The EP PerMed Venture Creator Programme successfully concluded its 2024 edition with an in-person final event held on 2 December 2025 in Barcelona, followed by the participation of the teams at Health Tech Forward on 3 – 4 December. The three-day programme brought together early-stage innovators, mentors, investors, and partners committed to advancing personalised medicine solutions across Europe.
Over the past months, participating teams progressed through a structured programme combining online workshops, tailored mentoring, and deep-dive expert sessions. The final event offered the teams an opportunity to showcase their progress, pitch in front of a jury of five experienced experts, and receive live feedback on their solutions, business models, and market strategies.
Strong Improvement & highly positive Feedback
Both mentors and teams expressed outstanding satisfaction with the programme:
- Mentors highlighted the impressive quality of the teams and the significant progress made during the one-on-one mentoring. Several mentors described the Venture Creator as one of the strongest early-stage programmes they have worked with, commending the structure, collaboration, and clarity of objectives.
- Teams appreciated the tangible improvements in their business cases and strategic thinking. Many reported that mentors went beyond traditional advisory roles – offering introductions within their networks, helping define regulatory routes, and providing hands-on market access insights.
Participating Teams in the Venture Creator Event
Nouilife
Country: Sweden
Sweden-based NouiLife® is developing a cutting-edge, non-invasive, real-time bladder monitoring device that employs electric signal communication and Embedded AI techniques to estimate the fluid dynamics of the user’s bladder and dehydration. The device ensures enhanced patient comfort by incorporating electrodes into specially designed e-textiles and biodegradable stretchable materials. This initiative aims to revolutionise digital hygiene care, optimise catheter use, and improve hydration management, ultimately reducing healthcare staff requirements by over 30% and transforming the healthcare delivery landscape.
UNOMR
Country: Switzerland
UNOMR revolutionises personalised medicine with its serial nanopore sensor, enabling precise and cost-effective protein analysis. Unlike current methods, our technology detects critical protein modifications like glycosylation (i.e. added sugars), which play a key role in diseases such as cancer and autoimmune disorders. By providing deeper insights into different types and locations of protein modifications, UNOMR supports earlier diagnosis, targeted drug development and improved treatments. Based on more than 6 years of research at ETH Zurich, a working prototype and two filed patents, we aim to set a new standard in proteomics advancing tailored healthcare solutions.
MYLeukaemia
Country: Portugal
MYLeukaemia believes that every blood cancer patient deserves personalised care with cutting-edge tech. MYLeukaemia is a research project that aims to drive the future of cancer therapy beyond current patient trial-and-error treatments with the design of the next generation of functional ex vivo drug testing powered by cutting-edge Organ-on-Chip technology. The project expects the MYLeukaemia Organ-on-Chip platform to advance knowledge of residual disease emergence in distinct leukaemia subtypes and translate this into the development of new prognostic markers and therapeutic targets for leukaemia eradication. The project also aims to accelerate drug development, reduce costs, and eliminate the need for animal testing.
Spatium
Country: France
Spatium aims to become a trusted third party at the intersection of clinical trial sponsors, biotech innovators, and pharmaceutical companies. Our mission is to bridge the gap between AI-driven insights and preclinical research, accelerating innovation in precision oncology.
Spatium leverages a portfolio of efficient and explainable AI-power multi-omics-based models to predict patient therapeutic responses and apply them to certify innovative human-based preclinical cell cultures, ensuring their seamless integration into safer, faster, and more ethical drug development workflows.
Cardiomo Europe B.V.
Country: The Netherlands
Cardiomo Europe BV is an innovative IT/HealthTech/MedTech company that offers wearable continuous remote monitoring with an AI engine to deliver real-time, actionable insights to detect arrhythmias and early warning for heart diseases that prevent life-threatening events and ensure better health through preventive care.
Zaneo
Country: France
ZANeo is transforming physiotherapy by delivering innovation and excellence to everyone. ZANeo makes personalised care a reality for every patient while enabling physiotherapists to track progress in real time. The AI-powered platform lets physiotherapists create and adjust personalised exercise plans for each patient’s unique needs, ensuring optimal rehabilitation. Patients can self-assess at home while professionals track progress in real time.
With its exclusive ZANeo Label, the platform guarantees equal access to top-quality care and empowers leading practitioners. ZANeo labels itself as the future of physiotherapy, where cutting-edge technology, personalised care, and excellence converge.
EVIIVE
Country: Switzerland
EVIIVE is developing a first-in-class liquid biopsy companion diagnostic test to enable precision immunotherapy selection for cancer patients. Using their single extracellular vesicle (EV) analysis platform, EVIIVE detects tumour and immune-derived EV biomarkers in plasma, providing a minimally invasive alternative to tissue biopsies. The test integrates seamlessly into clinical workflows, helping oncologists identify patients most likely to respond to immune checkpoint inhibitors. By improving patient stratification and treatment outcomes, EVIIVE’s solution advances precision oncology, reduces unnecessary toxicity, and optimises immunotherapy decision-making for personalised cancer treatment.